m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0027)
| Name |
Sarsasapogenin
|
||||
|---|---|---|---|---|---|
| Synonyms |
Parigenin; Sarsagenin; (25S)-5beta-Spirostan-3beta-ol; Sasarasapogenin; sarsapogenin; Sarsasapogenenin; UNII-CFS802C28F; Spirostan-3-ol, (3b,5b,25S)-; CFS802C28F; CHEBI:15578; (3beta,5beta,25S)-spirostan-3-ol; MFCD00270414; Spirostan-3-ol, (3beta,5beta,25S)- (9CI); Spirostan-3-ol; Sarsapogenine; 82597-74-8; (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-ol; (2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol; Sarsagenin [INN]; SR-05000002243; cogan; sarsasopogenin; Sarsasapogenine; Sarsasapogenin;; PYM50028; Parigenin;; (25S)-5-beta-spirostan-3-beta-ol; NSC 1615; EINECS 204-776-3; Sarsasapogenin, 95%; Sarsasapogenin, >=98%; (25S)-Spirostan-3beta-ol; (25S)-5-spirostan-3-ol; SCHEMBL180164; CHEMBL1171146; DTXSID00903921; HY-N0073; ZINC8218968; 2770AC; BDBM50442865; LMST01080007; s3607; AKOS015960455; Spirostan-3-ol, (3ss,5ss,25S)-; ACN-035281; CCG-208441; CS-7949; Spirostan-3-ol, (3beta,5beta,25S)-; AC-11191; AC-33951; AS-77870; Spirostan-3-ol, (3-beta,5-beta,25S)-; 5beta-Spirostan-3beta-ol, (25S)- (8CI); N1451; Resorufin-; A-D-glucuronide sodium salt, 98%; C03963; Q7424590; SR-05000002243-2; SR-05000002243-3; SR-05000002243-4; (1'R,2R,2'S,4'S,5S,7'S,8'R,9'S,12'S,13'S,16'S,18'R)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0?,?.0?,?.0??,??]icosane]-16'-ol
Click to Show/Hide
|
||||
| Status | Investigative | [1] | |||
| Structure |
 |
||||
| Formula |
C27H44O3
|
||||
| InChI |
InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17-,18+,19-,20+,21-,22-,23-,24-,25-,26-,27+/m0/s1
|
||||
| InChIKey |
GMBQZIIUCVWOCD-WWASVFFGSA-N
|
||||
| PubChem CID | |||||
Full List of m6A Targets Related to This Drug
Protein-glutamine gamma-glutamyltransferase 2 (TGM2)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | In rheumatoid arthritis fibroblast-like synoviocytes, m6A methylation-mediated gene Protein-glutamine gamma-glutamyltransferase 2 (TGM2) served as a promoter of RA-FLS proliferation by inducing DNA replication and cell cycle transition and inhibiting apoptosis through activating NF-Kappa-B signaling. TGM2 can be an attractive target and Sar was a novel anti-RA drug. | |||
| Responsed Disease | Rheumatoid arthritis | ICD-11: FA20 | ||
| Pathway Response | DNA replication | hsa03030 | ||
| Cell Process | DNA replication | |||
| Cell apoptosis | ||||
| In-vitro Model | MH7A | Normal | Homo sapiens | CVCL_0427 |
References